GGrantIndex
Sort

50,496 grants matching lung cancer

Rapid, Multiplexed Biosensor for Non-Invasive Detection of Gene Mutations and Personalization of Therapy in Non-Small Cell Lung Cancer

$997,685
Avni A Argun · Giner, Inc. · R44 · FY2023 · CA

Rapidly boosting innate immunity in the lungs to protect against pneumonia

$997,525
Brenton Scott · Pulmotect, Inc · R44 · FY2013 · AI

Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer

$997,515
Valerie Humblet · Collagen Medical, Llc · R44 · FY2016 · CA

Precision microRNA medicine in cancer

$997,500
Frank J. Slack · Beth Israel Deaconess Medical Center · R35 · FY2024 · CA

MethylScan for Early Detection of Liver and Lung Cancer

$997,285
Xiaohui Ni · Earlydiagnostics, Inc. · R44 · FY2022 · CA

MethylScan for Early Detection of Liver and Lung Cancer

$997,285
Xiaohui Ni · Earlydiagnostics, Inc. · R44 · FY2023 · CA

Development of novel therapeutics for cancer cachexia

$997,245
Scott Matthew Ebert · Emmyon, Inc. · R44 · FY2024 · CA

ACHIEVING BETTER CANCER DIAGNOSIS (ABCD): Identifying, supporting, and learning from marginalized patients who experience delayed cancer diagnosis

$996,882
Gordon David Schiff · Brigham And Women'S Hospital · R18 · FY2022 · HS

Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease

$996,801
Jennifer Joy Smith · Precyte, Inc. · R44 · FY2018 · AG

Late Effects of Treatment in Wilms Tumor Survivors and Offspring

$996,733
Norman E Breslow · Fred Hutchinson Cancer Research Center · R01 · FY2008 · CA

How do genome alterations cause human lung cancer?

$996,674
Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2019 · CA

Systemic regulation of metastasis

$996,660
David Charles Lyden · Weill Medical Coll Of Cornell Univ · R35 · FY2022 · CA

CHEMOPREVENTION OF LUNG AND ESOPHAGEAL CANCER

$996,601
University Of Minnesota Twin Cities · P01 · FY2001 · CA

Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer

$996,270
Reuben J Shaw · Salk Institute For Biological Studies · R35 · FY2017 · CA

Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer

$996,232
Jennifer Joy Smith · Precyte, Inc. · R44 · FY2018 · CA

Development of TIMP-2 derivatives or strategies as biologic therapies for cancer

$995,769
William Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

CardioWatch: An Omics-Based Prediction Assay for Cardiac Late Effects ofAcute Radiation

$995,681
John B. Tyburski · Nelson Scientific Labs Llc · R44 · FY2023 · AI

Prostate Cancer Studies

$995,563
Michael Cook · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA

Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency

$995,166
Alan S. Wayne · Children'S Hospital Of Los Angeles · U01 · FY2022 · AI

Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance

$995,148
Pasi A Janne · Dana-Farber Cancer Inst · R35 · FY2024 · CA

Building a Sustainable Indian Tribal Infrastructure for Translational Research

$995,133
Carolyn June Strickland · University Of Washington · RC4 · FY2010 · NR

Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies

$995,112
Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human

$995,100
Joshua Alfaro · Pharmain Corporation · R44 · FY2023 · CA

Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human

$995,099
Joshua Alfaro · Pharmain Corporation · R44 · FY2024 · CA

Center for Interventional Oncology

$995,007
Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2010 · CA